TEVA.TA - Teva Pharmaceutical Industries Limited

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
6,085.00
+25.00 (+0.41%)
As of 10:50AM IST. Market open.
Stock chart is not supported by your current browser
Previous Close6,060.00
Open6,100.00
Bid6,085.00 x 200
Ask6,086.00 x 34100
Day's Range6,076.00 - 6,100.00
52 Week Range5,440.00 - 9,475.00
Volume162,971
Avg. Volume765,083
Market Cap61.989B
Beta (3Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-2.35
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-28
1y Target Est26.00
  • Teva CEO on the pharmaceutical industry
    Yahoo Finance Videolast month

    Teva CEO on the pharmaceutical industry

    Teva Pharmaceutical Industries CEO Kåre Schultz joins The Final Round to talk about the pharmaceutical industry, including drug pricing, and the state of the company.

  • Teva slides on forecast, drags other generic drugmakers
    Reuters Videoslast month

    Teva slides on forecast, drags other generic drugmakers

    U.S.-listed shares of Teva Pharmaceutical fell after the company reported Q4 results and gave poor 2019 outlook. Fred Katayama reports.

  • 3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade
    Motley Fool8 days ago

    3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade

    These healthcare giants are taking the word "value" to an extreme.

  • Why Teva Pharmaceutical Industries Stock Sank in February
    Motley Fool14 days ago

    Why Teva Pharmaceutical Industries Stock Sank in February

    Teva's 2019 outlook sent investors packing last month.

  • Business Wire18 days ago

    Teva Announces Launch of an Authorized Generic of Flector® Patch (diclofenac epolamine topical patch) in the United States

    Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Flector®1 Patch, 1.3 %, in the U.S. Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions. “The launch of our authorized generic of Flector® Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” said Brendan O’Grady, EVP and Head of North America Commercial.

  • Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool20 days ago

    Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript

    ATRS earnings call for the period ending December 31, 2018.

  • Benzinga28 days ago

    The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...

  • Teva Pharmaceutical’s Generics Business Trends in 2019
    Market Realist28 days ago

    Teva Pharmaceutical’s Generics Business Trends in 2019

    Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Generics business trends In its fourth-quarter earnings presentation, Teva Pharmaceutical (TEVA) guided for a small fall in revenue in its North American generics

  • TheStreet.com28 days ago

    Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission

    shares were indicated lower in pre-market trading Wednesday after the drugmaker reached a settlement with the Federal Trade Commission over allegations it delayed the release of generic medicines through agreements with pharmaceutical rivals. The FTC settlement, made public last night in Washington, will essentially prevent Teva from cutting so-called "pay for delay" deals in the future, with the Commission sees as costing U.S. consumers billions in higher drug prices. The European Commission has also targeted similar deals in the past, including a pact between Teva and rival Cephalon over a sleep disorder drug Provigil before the two groups combined in 2012.

  • Reuters28 days ago

    U.S. settles with Teva over keeping generic drugs off market

    The U.S. government has reached a settlement with Teva Pharmaceuticals Industries Ltd over charges that its agreements with rivals impeded consumer access to lower-priced generic drugs. The Federal Trade Commission on Tuesday said it had settled three reverse payment fights with units of Teva, which will be prohibited from making similar agreements with competitors in the future. The deal is often struck to resolve patent litigation.

  • Business Wire28 days ago

    Teva Finalizes Settlement with Federal Trade Commission to Resolve All Outstanding Litigation between the Parties

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a settlement with the Federal Trade Commission (FTC) that will resolve all outstanding litigation between the parties. Under the terms of the settlement, which is subject to court approval, the FTC will dismiss its claims against Teva and its affiliates in three outstanding cases, and the parties will modify certain terms in their 2015 consent decree. Teva will not pay any additional money to the FTC as part of this settlement.

  • Reuters28 days ago

    U.S. settles three reverse payment fights with Teva units

    The U.S. Federal Trade Commission has settled three reverse payment fights with units of Teva Pharmaceuticals Industries Ltd, the agency said on Tuesday. Under the settlement agreement, Teva will be prohibited ...

  • Reuters29 days ago

    U.S. top court rejects Maryland bid to revive drug price-gouging law

    The U.S. Supreme Court on Tuesday rejected Maryland's bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs. The justices declined to take up Maryland's appeal of a 2018 federal appeals court ruling that struck down the state's law, That ruling held that Maryland had regulated wholesale pricing by the companies in violation of the U.S. Constitution's bar on state-level regulation of interstate commerce.

  • GuruFocus.com29 days ago

    Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Warning! GuruFocus has detected 2 Warning Signs with TEVA. For the last quarter Teva Pharmaceutical Industries Ltd reported a revenue of $4.6 billion, compared with the revenue of $5.4 billion during the same period a year ago.

  • Does Teva Have Attractive Cash Flow and Net Debt Profiles?
    Market Realist29 days ago

    Does Teva Have Attractive Cash Flow and Net Debt Profiles?

    Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Free cash flow projectionsIn its fourth-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) guided for free cash flow of $1.6 billion–$2.0 billion in

  • How Is Teva Pharmaceutical Controlling Its Expenses?
    Market Realist29 days ago

    How Is Teva Pharmaceutical Controlling Its Expenses?

    Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Cost-controlling initiativesIn its fourth-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) highlighted a $2.2 billion fall in its spending base from

  • Reuters29 days ago

    Teva expects sales injection from U.S. EpiPen market

    Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to claim about 25 percent of the U.S. market by the end of the year, CEO Kare Schultz said on Tuesday, as the company closes in on a return to growth in 2020. Wall Street has viewed the EpiPen rival as a welcome profit-booster for Teva as it contends with declining U.S. margins for its older generic medicines, competition for multiple sclerosis treatment Copaxone and costly acquisitions.

  • TheStreet.comlast month

    Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

    Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.

  • Moody'slast month

    Teva Pharmaceutical Finance Netherlands II BV -- Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Teva Pharmaceutical Industries Ltd and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Teva Pharmaceutical Industries (TEVA) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Teva Pharmaceutical Industries (TEVA) Q4 2018 Earnings Conference Call Transcript

    TEVA earnings call for the period ending December 31, 2018.

  • Benzingalast month

    Credit Suisse Stays Sidelined On Teva: 'Our Growth Expectations Are Below That Of The Company'

    Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) reported disappointing fourth-quarter earnings Wednesday before the market open, sending its shares down about 8 percent. The Analyst Credit Suisse analyst ...

  • The Wall Street Journallast month

    [$$] King of Generics Pushes Into Biotech Drugs

    The world’s largest maker of generic drugs is looking for growth in an unlikely place: high-price biotech medicines. Teva Pharmaceutical Industries Ltd., which supplies more than one in 10 drugs taken in the U.S., has struggled in recent years with slumping generics prices and heavy debt. “We figured out a strategy where we’d continue to be leaders in generics but really focus our R&D on innovative biologics and biosimilars,” Chief Executive Kåre Schultz said in an interview.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of TEVA.TA earnings conference call or presentation 13-Feb-19 1:00pm GMT

    Q4 2018 Teva Pharmaceutical Industries Ltd Earnings Call

  • TheStreet.comlast month

    3 Things to Know at Market Close: Teva, Google and Cisco

    is anticipating a trough for 2019 but this is a natural development as the company restructures, according to CEO Kare Schultz. Schultz explained his outlook in an interview with TheStreet's Kevin Curran, noting that the performance hit the company's conservative guidance for the fourth quarter and added that Wall Street was overly bullish in its 2019 targets. Apple's Big Payday Comes From...Google?

  • Why Teva Pharmaceutical Industries, McDermott International, and Groupon Slumped Today
    Motley Foollast month

    Why Teva Pharmaceutical Industries, McDermott International, and Groupon Slumped Today

    Find out what made these stocks lose ground despite a good session for the markets.